tirzepatide eu approval Eli Lilly targets FDA for weight loss medication FDA approval for Zepbound (tirzepatide)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2028

Mientras millones de personas recurren a Ozempic, Wegovy o Dutide para perder peso, mdicos e investigadores coinciden en que an falta informacin crucial sobre los efectos del consumo prolongado

Our findings highlight that there are differences in the characteristics of people and the mechanisms that drive the development of HF in diabetes and the type of HF, Pop-Busui told Healio

Patients with type 2 diabetes should have regular cardiovascular risk assessment, and any new cardiac symptoms should prompt thorough evaluation